Compare PPL & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPL | NTRA |
|---|---|---|
| Founded | 1920 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9B | 28.0B |
| IPO Year | 2007 | 2015 |
| Metric | PPL | NTRA |
|---|---|---|
| Price | $38.16 | $200.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $40.00 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 6.8M | 1.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ 32.50 | 0.65 |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $9,042,000,000.00 | $210,939,000.00 |
| Revenue This Year | $6.76 | $18.16 |
| Revenue Next Year | $6.09 | $20.00 |
| P/E Ratio | $23.94 | ★ N/A |
| Revenue Growth | ★ 6.85 | N/A |
| 52 Week Low | $32.50 | $125.38 |
| 52 Week High | $39.09 | $256.36 |
| Indicator | PPL | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 50.15 |
| Support Level | $35.31 | $194.03 |
| Resistance Level | $38.20 | $204.34 |
| Average True Range (ATR) | 0.66 | 7.31 |
| MACD | -0.04 | 0.46 |
| Stochastic Oscillator | 63.56 | 82.21 |
PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.